JP2019535715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535715A5 JP2019535715A5 JP2019525851A JP2019525851A JP2019535715A5 JP 2019535715 A5 JP2019535715 A5 JP 2019535715A5 JP 2019525851 A JP2019525851 A JP 2019525851A JP 2019525851 A JP2019525851 A JP 2019525851A JP 2019535715 A5 JP2019535715 A5 JP 2019535715A5
- Authority
- JP
- Japan
- Prior art keywords
- azetidine
- difluorophenoxy
- compound
- pharmaceutically acceptable
- isotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 4
- TXTVXNRODZFMEX-UHFFFAOYSA-N 3-(2,3-difluorophenoxy)azetidine Chemical compound FC1=CC=CC(OC2CNC2)=C1F TXTVXNRODZFMEX-UHFFFAOYSA-N 0.000 claims 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- -1 3,5-difluorophenoxy Chemical group 0.000 claims 2
- UGLPJXJCBSHGRH-UHFFFAOYSA-N 3-(2,3,5,6-tetrafluorophenoxy)azetidine Chemical compound FC1=C(OC2CNC2)C(=C(C=C1F)F)F UGLPJXJCBSHGRH-UHFFFAOYSA-N 0.000 claims 2
- VXXACJCOSVCADM-UHFFFAOYSA-N 3-(3,5-difluorophenoxy)azetidine Chemical compound FC1=CC(F)=CC(OC2CNC2)=C1 VXXACJCOSVCADM-UHFFFAOYSA-N 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- PIMRYTXJZVROJO-UHFFFAOYSA-N 3-(2,3,4-trifluorophenoxy)azetidine Chemical compound FC1=C(F)C(F)=CC=C1OC1CNC1 PIMRYTXJZVROJO-UHFFFAOYSA-N 0.000 claims 1
- QSZKBJBRWVQHHH-UHFFFAOYSA-N 3-(2,4,5-trifluorophenoxy)azetidine Chemical compound FC1=C(OC2CNC2)C=C(C(=C1)F)F QSZKBJBRWVQHHH-UHFFFAOYSA-N 0.000 claims 1
- XXTYTFVOMHMMJV-UHFFFAOYSA-N 3-(2,4,6-trifluorophenoxy)azetidine Chemical compound FC1=C(OC2CNC2)C(=CC(=C1)F)F XXTYTFVOMHMMJV-UHFFFAOYSA-N 0.000 claims 1
- UTNJOKZHZHVICP-UHFFFAOYSA-N 3-(2,4-difluorophenoxy)azetidine Chemical compound FC1=CC(F)=CC=C1OC1CNC1 UTNJOKZHZHVICP-UHFFFAOYSA-N 0.000 claims 1
- DZGOPXZJIMJNDN-UHFFFAOYSA-N 3-(2,4-difluorophenoxy)azetidine;hydrochloride Chemical compound Cl.FC1=CC(F)=CC=C1OC1CNC1 DZGOPXZJIMJNDN-UHFFFAOYSA-N 0.000 claims 1
- XECNNPZISUHUNI-UHFFFAOYSA-N 3-(2,5-difluorophenoxy)azetidine Chemical compound FC1=CC=C(F)C(OC2CNC2)=C1 XECNNPZISUHUNI-UHFFFAOYSA-N 0.000 claims 1
- NNFXZJSCCQBCFR-UHFFFAOYSA-N 3-(2,6-difluorophenoxy)azetidine Chemical compound FC1=CC=CC(F)=C1OC1CNC1 NNFXZJSCCQBCFR-UHFFFAOYSA-N 0.000 claims 1
- UWJAEZJEHAUARH-UHFFFAOYSA-N 3-(2,6-difluorophenoxy)azetidine hydrochloride Chemical compound Cl.Fc1cccc(F)c1OC1CNC1 UWJAEZJEHAUARH-UHFFFAOYSA-N 0.000 claims 1
- LGYZUROTBPYFOS-UHFFFAOYSA-N 3-(3,4-difluorophenoxy)azetidine;hydrochloride Chemical compound Cl.C1=C(F)C(F)=CC=C1OC1CNC1 LGYZUROTBPYFOS-UHFFFAOYSA-N 0.000 claims 1
- DYZARWVJCDJAHX-UHFFFAOYSA-N 3-(3,5-difluorophenoxy)azetidine;hydrochloride Chemical compound Cl.FC1=CC(F)=CC(OC2CNC2)=C1 DYZARWVJCDJAHX-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 claims 1
- 210000003710 cerebral cortex Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545 | 2016-11-18 | ||
| EP16199545.1 | 2016-11-18 | ||
| PCT/EP2017/079666 WO2018091687A1 (en) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535715A JP2019535715A (ja) | 2019-12-12 |
| JP2019535715A5 true JP2019535715A5 (enExample) | 2020-11-12 |
| JP6990702B2 JP6990702B2 (ja) | 2022-01-13 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019525851A Active JP6990702B2 (ja) | 2016-11-18 | 2017-11-17 | 皮質カテコールアミン作動性神経伝達のモジュレーターとして有用な新規アゼチジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (enExample) |
| EP (1) | EP3541784B1 (enExample) |
| JP (1) | JP6990702B2 (enExample) |
| CN (1) | CN109963834B (enExample) |
| DK (1) | DK3541784T5 (enExample) |
| ES (1) | ES2962865T3 (enExample) |
| FI (1) | FI3541784T3 (enExample) |
| PL (1) | PL3541784T3 (enExample) |
| PT (1) | PT3541784T (enExample) |
| WO (1) | WO2018091687A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| WO2025008506A1 (en) | 2023-07-06 | 2025-01-09 | Integrative Research Laboratories Sweden Ab | 3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy |
| AU2024289298A1 (en) | 2023-07-06 | 2026-01-15 | Integrative Research Laboratories Sweden Ab | Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| EP2367787B1 (en) | 2008-11-24 | 2013-01-09 | NSAB, Filial af NeuroSearch Sweden AB, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| JP5621087B2 (ja) * | 2008-11-24 | 2014-11-05 | インテグレイティブ・リサーチ・ラボラトリーズ・スウェーデン・アーベー | 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体 |
| WO2010084428A1 (en) | 2009-01-20 | 2010-07-29 | Pfizer Inc. | Substituted pyrazinone amides |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| JP2013519732A (ja) * | 2010-02-17 | 2013-05-30 | アムジエン・インコーポレーテツド | 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体 |
| EP2718295A1 (en) | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| AP2014007820A0 (en) * | 2012-01-26 | 2014-07-31 | Lundbeck & Co As H | PDE9 inhibitors with imidazo triazinone backbone |
| BR112017000160A2 (pt) | 2014-08-27 | 2017-10-31 | Hoffmann La Roche | derivados de azetidina substituidos como ligantes de taar |
| TWI601712B (zh) * | 2014-11-05 | 2017-10-11 | 達特神經科學（開曼）有限責任公司 | 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物 |
| AU2016263510B2 (en) * | 2015-05-20 | 2020-03-12 | Integrative Research Laboratories Sweden Ab | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| WO2017045648A1 (zh) | 2015-09-18 | 2017-03-23 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| JOP20190077A1 (ar) * | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
-
2017
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502092A5 (enExample) | ||
| JP2015531764A5 (enExample) | ||
| JP2013536833A5 (enExample) | ||
| JP2019505541A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| JP2020511461A5 (enExample) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2008513516A5 (enExample) | ||
| MX2010005717A (es) | Derivados de isoxazolo-piridina. | |
| JP2015508092A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2015512951A5 (enExample) | ||
| MX386258B (es) | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas | |
| JP2016534063A5 (enExample) | ||
| JP2016506959A5 (enExample) | ||
| MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| JP2004534816A5 (enExample) | ||
| JP2013523733A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| JP2019535723A5 (enExample) | ||
| JP2013507374A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2012518634A5 (enExample) |